559 related articles for article (PubMed ID: 36891310)
1. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.
Zhang X; Zhang H; Lan H; Wu J; Xiao Y
Front Immunol; 2023; 14():1101495. PubMed ID: 36891310
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T-cell therapy for multiple myeloma.
Wang Z; Chen C; Wang L; Jia Y; Qin Y
Front Immunol; 2022; 13():1050522. PubMed ID: 36618390
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges.
Dhakal B; Hari PN; Usmani SZ; Hamadani M
Bone Marrow Transplant; 2021 Jan; 56(1):9-19. PubMed ID: 32770147
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
Choi T; Kang Y
Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
[TBL] [Abstract][Full Text] [Related]
5. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.
Reyes KR; Liu YC; Huang CY; Banerjee R; Martin T; Wong SW; Wolf JL; Arora S; Shah N; Chari A; Chung A
Blood Adv; 2024 May; 8(9):2207-2216. PubMed ID: 38429087
[TBL] [Abstract][Full Text] [Related]
7. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.
van de Donk NWCJ; Themeli M; Usmani SZ
Blood Cancer Discov; 2021 Jul; 2(4):302-318. PubMed ID: 34386775
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
9. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
10. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma.
Feng Y; Liu X; Li X; Zhou Y; Song Z; Zhang J; Shi B; Wang J
Oncoimmunology; 2021; 10(1):1959102. PubMed ID: 34434610
[TBL] [Abstract][Full Text] [Related]
11. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
12. [Future therapeutic strategies for multiple myeloma].
Ishida T
Rinsho Ketsueki; 2022; 63(6):635-645. PubMed ID: 35831199
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.
Metelo AM; Jozwik A; Luong LA; Dominey-Foy D; Graham C; Attwood C; Inam S; Dunlop A; Sanchez K; Cuthill K; Rice C; Streetly M; Bentley T; Boldajipour B; Sommer C; Sasu B; Benjamin R
Cancer Res Commun; 2022 Mar; 2(3):158-171. PubMed ID: 36874402
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
15. [CAR-T therapy for multiple myeloma].
Ri M
Rinsho Ketsueki; 2023; 64(11):1456-1464. PubMed ID: 38072434
[TBL] [Abstract][Full Text] [Related]
16. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
17. Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma.
Beauvais D; Danhof S; Hayden PJ; Einsele H; Yakoub-Agha I
Curr Opin Oncol; 2020 Sep; 32(5):418-426. PubMed ID: 32740095
[TBL] [Abstract][Full Text] [Related]
18. Current use of CAR T cells to treat multiple myeloma.
Firestone RS; Mailankody S
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):340-347. PubMed ID: 38066841
[TBL] [Abstract][Full Text] [Related]
19. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
Front Immunol; 2022; 13():927153. PubMed ID: 35757715
[TBL] [Abstract][Full Text] [Related]
20. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]